Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

Christopher Lobo, Gilberto Lopes, Odalys Baez, Aurelio Castrellon, Annapoorna Ferrell, Connie Higgins, Erin Hurley, Judith Hurley, Isildinha Reis, Stephen Richman, Pearl Seo, Orlando Silva, Joyce Slingerland, Keleni Tukia, Catherine Welsh, Stefan Glück

Research output: Contribution to journalArticle

Abstract

In order to examine the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-P) in combination with bevacizumab (B) and gemcitabine (G) for the first-line treatment of patients with HER2-negative metastatic breast cancer (MBC). In this single-center, open-label phase II trial, patients with HER2-negative MBC received gemcitabine 1500 mg/m2, nab-paclitaxel 150 mg/m2, and bevacizumab 10 mg/kg (each administered intravenously) on days 1 and 15 of a 28-day cycle. The primary end point was progression free survival (PFS); secondary end points were overall response rate (ORR), complete (CR) and partial (PR) response rates, clinical benefit (ORR + stable disease), overall survival (OS), and safety. Thirty patients were enrolled. One patient was ineligible and was not included in analysis. Median PFS was 10.4 months (95% CI: 5.6-15.2 months). ORR was 75.9%, comprising eight (27.6%) CRs and 14 (48.3%) PRs; five patients had stable disease (SD) and two patients (6.9%) had progressive disease (PD) as their best response. The clinical benefit rate was 93.1% (27/29) in the overall group and 84.6% in the triple-negative cohort (11/13). The 18-month survival rate was 77.2% (95% CI: 51.1-90.5%). Eight (27.6%) patients experienced grade 3 or 4 toxicity: grade 4 neutropenic fever (n = 1) and grade 3 infection (n = 6), leukopenia, thrombocytopenia, peripheral neuropathy, seizure, shortness of breath, hematuria, and cardiac tamponade (one each). First-line therapy with nab-P, B, and G demonstrated a median PFS of 10.4 months and a 75.9% ORR with acceptable toxicity; this novel combination warrants investigation in a randomized study.

Original languageEnglish (US)
Pages (from-to)427-435
Number of pages9
JournalBreast Cancer Research and Treatment
Volume123
Issue number2
DOIs
StatePublished - Sep 2010

Fingerprint

gemcitabine
Breast Neoplasms
Disease-Free Survival
Nanoparticles
Therapeutics
Safety
Cardiac Tamponade
Leukopenia
Peripheral Nervous System Diseases
Hematuria
Bevacizumab
130-nm albumin-bound paclitaxel
Thrombocytopenia
Dyspnea
Seizures
Fever
Survival Rate

Keywords

  • Bevacizumab
  • First-line therapy
  • Gemcitabine
  • HER2-negative metastatic breast cancer
  • Nab-paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. / Lobo, Christopher; Lopes, Gilberto; Baez, Odalys; Castrellon, Aurelio; Ferrell, Annapoorna; Higgins, Connie; Hurley, Erin; Hurley, Judith; Reis, Isildinha; Richman, Stephen; Seo, Pearl; Silva, Orlando; Slingerland, Joyce; Tukia, Keleni; Welsh, Catherine; Glück, Stefan.

In: Breast Cancer Research and Treatment, Vol. 123, No. 2, 09.2010, p. 427-435.

Research output: Contribution to journalArticle

Lobo, C, Lopes, G, Baez, O, Castrellon, A, Ferrell, A, Higgins, C, Hurley, E, Hurley, J, Reis, I, Richman, S, Seo, P, Silva, O, Slingerland, J, Tukia, K, Welsh, C & Glück, S 2010, 'Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer', Breast Cancer Research and Treatment, vol. 123, no. 2, pp. 427-435. https://doi.org/10.1007/s10549-010-1002-0
Lobo, Christopher ; Lopes, Gilberto ; Baez, Odalys ; Castrellon, Aurelio ; Ferrell, Annapoorna ; Higgins, Connie ; Hurley, Erin ; Hurley, Judith ; Reis, Isildinha ; Richman, Stephen ; Seo, Pearl ; Silva, Orlando ; Slingerland, Joyce ; Tukia, Keleni ; Welsh, Catherine ; Glück, Stefan. / Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. In: Breast Cancer Research and Treatment. 2010 ; Vol. 123, No. 2. pp. 427-435.
@article{2cac2f72a26b4200873c8fac48854956,
title = "Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer",
abstract = "In order to examine the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-P) in combination with bevacizumab (B) and gemcitabine (G) for the first-line treatment of patients with HER2-negative metastatic breast cancer (MBC). In this single-center, open-label phase II trial, patients with HER2-negative MBC received gemcitabine 1500 mg/m2, nab-paclitaxel 150 mg/m2, and bevacizumab 10 mg/kg (each administered intravenously) on days 1 and 15 of a 28-day cycle. The primary end point was progression free survival (PFS); secondary end points were overall response rate (ORR), complete (CR) and partial (PR) response rates, clinical benefit (ORR + stable disease), overall survival (OS), and safety. Thirty patients were enrolled. One patient was ineligible and was not included in analysis. Median PFS was 10.4 months (95{\%} CI: 5.6-15.2 months). ORR was 75.9{\%}, comprising eight (27.6{\%}) CRs and 14 (48.3{\%}) PRs; five patients had stable disease (SD) and two patients (6.9{\%}) had progressive disease (PD) as their best response. The clinical benefit rate was 93.1{\%} (27/29) in the overall group and 84.6{\%} in the triple-negative cohort (11/13). The 18-month survival rate was 77.2{\%} (95{\%} CI: 51.1-90.5{\%}). Eight (27.6{\%}) patients experienced grade 3 or 4 toxicity: grade 4 neutropenic fever (n = 1) and grade 3 infection (n = 6), leukopenia, thrombocytopenia, peripheral neuropathy, seizure, shortness of breath, hematuria, and cardiac tamponade (one each). First-line therapy with nab-P, B, and G demonstrated a median PFS of 10.4 months and a 75.9{\%} ORR with acceptable toxicity; this novel combination warrants investigation in a randomized study.",
keywords = "Bevacizumab, First-line therapy, Gemcitabine, HER2-negative metastatic breast cancer, Nab-paclitaxel",
author = "Christopher Lobo and Gilberto Lopes and Odalys Baez and Aurelio Castrellon and Annapoorna Ferrell and Connie Higgins and Erin Hurley and Judith Hurley and Isildinha Reis and Stephen Richman and Pearl Seo and Orlando Silva and Joyce Slingerland and Keleni Tukia and Catherine Welsh and Stefan Gl{\"u}ck",
year = "2010",
month = "9",
doi = "10.1007/s10549-010-1002-0",
language = "English (US)",
volume = "123",
pages = "427--435",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

AU - Lobo, Christopher

AU - Lopes, Gilberto

AU - Baez, Odalys

AU - Castrellon, Aurelio

AU - Ferrell, Annapoorna

AU - Higgins, Connie

AU - Hurley, Erin

AU - Hurley, Judith

AU - Reis, Isildinha

AU - Richman, Stephen

AU - Seo, Pearl

AU - Silva, Orlando

AU - Slingerland, Joyce

AU - Tukia, Keleni

AU - Welsh, Catherine

AU - Glück, Stefan

PY - 2010/9

Y1 - 2010/9

N2 - In order to examine the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-P) in combination with bevacizumab (B) and gemcitabine (G) for the first-line treatment of patients with HER2-negative metastatic breast cancer (MBC). In this single-center, open-label phase II trial, patients with HER2-negative MBC received gemcitabine 1500 mg/m2, nab-paclitaxel 150 mg/m2, and bevacizumab 10 mg/kg (each administered intravenously) on days 1 and 15 of a 28-day cycle. The primary end point was progression free survival (PFS); secondary end points were overall response rate (ORR), complete (CR) and partial (PR) response rates, clinical benefit (ORR + stable disease), overall survival (OS), and safety. Thirty patients were enrolled. One patient was ineligible and was not included in analysis. Median PFS was 10.4 months (95% CI: 5.6-15.2 months). ORR was 75.9%, comprising eight (27.6%) CRs and 14 (48.3%) PRs; five patients had stable disease (SD) and two patients (6.9%) had progressive disease (PD) as their best response. The clinical benefit rate was 93.1% (27/29) in the overall group and 84.6% in the triple-negative cohort (11/13). The 18-month survival rate was 77.2% (95% CI: 51.1-90.5%). Eight (27.6%) patients experienced grade 3 or 4 toxicity: grade 4 neutropenic fever (n = 1) and grade 3 infection (n = 6), leukopenia, thrombocytopenia, peripheral neuropathy, seizure, shortness of breath, hematuria, and cardiac tamponade (one each). First-line therapy with nab-P, B, and G demonstrated a median PFS of 10.4 months and a 75.9% ORR with acceptable toxicity; this novel combination warrants investigation in a randomized study.

AB - In order to examine the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-P) in combination with bevacizumab (B) and gemcitabine (G) for the first-line treatment of patients with HER2-negative metastatic breast cancer (MBC). In this single-center, open-label phase II trial, patients with HER2-negative MBC received gemcitabine 1500 mg/m2, nab-paclitaxel 150 mg/m2, and bevacizumab 10 mg/kg (each administered intravenously) on days 1 and 15 of a 28-day cycle. The primary end point was progression free survival (PFS); secondary end points were overall response rate (ORR), complete (CR) and partial (PR) response rates, clinical benefit (ORR + stable disease), overall survival (OS), and safety. Thirty patients were enrolled. One patient was ineligible and was not included in analysis. Median PFS was 10.4 months (95% CI: 5.6-15.2 months). ORR was 75.9%, comprising eight (27.6%) CRs and 14 (48.3%) PRs; five patients had stable disease (SD) and two patients (6.9%) had progressive disease (PD) as their best response. The clinical benefit rate was 93.1% (27/29) in the overall group and 84.6% in the triple-negative cohort (11/13). The 18-month survival rate was 77.2% (95% CI: 51.1-90.5%). Eight (27.6%) patients experienced grade 3 or 4 toxicity: grade 4 neutropenic fever (n = 1) and grade 3 infection (n = 6), leukopenia, thrombocytopenia, peripheral neuropathy, seizure, shortness of breath, hematuria, and cardiac tamponade (one each). First-line therapy with nab-P, B, and G demonstrated a median PFS of 10.4 months and a 75.9% ORR with acceptable toxicity; this novel combination warrants investigation in a randomized study.

KW - Bevacizumab

KW - First-line therapy

KW - Gemcitabine

KW - HER2-negative metastatic breast cancer

KW - Nab-paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=77956184020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956184020&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-1002-0

DO - 10.1007/s10549-010-1002-0

M3 - Article

C2 - 20585851

AN - SCOPUS:77956184020

VL - 123

SP - 427

EP - 435

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -